2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-103487
    Uprifosbuvir 1496551-77-9 98.17%
    Uprifosbuvir is an antiviral agent. Uprifosbuvir is a NS5b inhibitor developed for the research of chronic hepatitis C virus.
    Uprifosbuvir
  • HY-106254
    Vapendavir 439085-51-5 99.93%
    Vapendavir (BTA798) is a potent enteroviral capsid binder (CB). Vapendavir (BTA798) possesses potent antiviral activity for enterovirus 71 (EV71) replication, with EC50 values of 0.5-1.4 μM in different EV71 strains.
    Vapendavir
  • HY-112564
    JNJ-632 1572510-42-9 99.94%
    JNJ-632 is a hepatitis B virus (HBV) capsid assembly modulator (CAM).
    JNJ-632
  • HY-119378
    AK 295 160399-35-9 99.0%
    AK 295 (CX 295) is a selective calpain inhibitor. AK 295 can inhibit apoptosis through a calpain-dependent pathway. AK 295 shows potent neuroprotective effect. AK 295 can inhibit the activity of the cysteine protease calpain and reduce myocardial injury. AK 295 can be used for the researches of infection, inflammation, cardiovascular and neurological disease, such as stroke and viral myocarditis.
    AK 295
  • HY-120060
    GNF6702 1799329-72-8 98.33%
    GNF6702 is a selective inhibitor of the kinetoplastid proteasome. GNF6702 clears parasites in murine models of leishmaniasis, Chagas disease, and human African trypanosomiasis.
    GNF6702
  • HY-147020
    Coronastat 2922281-15-8 98.0%
    Coronastat is a potent inhibitor of the SARS-CoV-2 3CL protease. The SARS-CoV-2 3CL protease is a critical agent target for small molecule COVID-19, given its likely agentgability and essentiality in the viral maturation and replication cycle.
    Coronastat
  • HY-B0671R
    Vancomycin (Standard) 1404-90-6
    Vancomycin (Standard) is the analytical standard of Vancomycin. This product is intended for research and analytical applications. Vancomycin is an antibiotic for the treatment of bacterial infections.
    Vancomycin (Standard)
  • HY-B1907A
    Rifamycin 6998-60-3 98.06%
    Rifamycin (Rifamycin SV) is an orally active ansamycin antibiotic. Rifamycin inhibits DNA-dependent RNA synthesis. Rifamycin has antibacterial activity against Mycobacterium tuberculosis. Rifamycin interferes with hepatic bile acid metabolism. Rifamycin has anti-inflammatory effects. Rifamycin can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation.
    Rifamycin
  • HY-135811A
    Desethyl chloroquine diphosphate 247912-76-1 99.72%
    Desethyl chloroquine diphosphate is a major desethyl metabolite of Chloroquine. Chloroquine diphosphate is an inhibitor of autophagy and toll-like receptors (TLRs). Desethyl chloroquine diphosphate possesses antiplasmodic activity.
    Desethyl chloroquine diphosphate
  • HY-134541S6
    SM-102-d4 99.81%
    SM-102-d4 is the deuterium labeled SM-102 (HY-134541). SM-102 is an amino cationic lipid useful in the formation of lipid nanoparticles (LNPs). SM-102 has higher transfection efficiency. SM-102 plays an important role in the effectiveness of lipid nanoparticles (LNPs) in delivering mRNA therapeutics and vaccines.
    SM-102-d4
  • HY-10522
    LEDGIN6 957890-42-5 99.62%
    LEDGIN6 (CX05168) is a quinoline-based protein-protein interaction inhibitor of LEDGF/p75 and HIV integrase.
    LEDGIN6
  • HY-44809
    Izilendustat 1303512-02-8
    Izilendustat is a potent prolyl hydroxylase inhibitor. Izilendustat competitively inhibits HIFPH2 activity, blocks HIF-1α degradation, stabilizes HIF-1α and HIF-2α proteins, and upregulates downstream target gene expression. Izilendustat can reduce intestinal inflammation and damage, enhance the ability of phagocytes to clear pathogens, and improve ischemia-related pathological phenotypes. Izilendustat can be used for the research of inflammatory bowel disease, ischemic vascular disease and anemia.
    Izilendustat
  • HY-101663
    Ruzasvir 1613081-64-3
    Ruzasvir (MK-8408) is an orally active inhibitor for genotypic HCV nonstructural protein 5A (NS5A), which inhibits the replication of NS5A mutants GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a and GT4a with EC90 ranging from 0.003 to 0.067 nM. Ruzasvir exhibits good pharmacokinetic characters in rhesus monkey model.
    Ruzasvir
  • HY-109014
    Tenofovir exalidex 911208-73-6 99.82%
    Tenofovir exalidex (CMX157) is a lipid conjugate of the acyclic nucleotide analog Tenofovir with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. Tenofovir exalidex is active against all major subtypes of HIV-1 and HIV-2 in fresh human PBMCs and against all HIV-1 strains evaluated in monocyte-derived macrophages, with EC50s ranging between 0.2 and 7.2 nM. CMX157 is orally available and has no apparent toxicity. Tenofovir exalidex also shows antiviral activity against HBV.
    Tenofovir exalidex
  • HY-115440
    CRS3123 dihydrochloride 1013915-99-5 99.11%
    CRS3123 (REP-3123) dihydrochloride, a fully synthetic antibacterial agent, potently inhibits methionyl-tRNA synthetase (MetRS) of Clostridioides difficile, inhibiting Clostridioides difficile toxin production and spore formation. CRS3123 dihydrochloride is an oral agent for the research of Clostridioides difficile infection (CDI).
    CRS3123 dihydrochloride
  • HY-136149
    Mpro inhibitor N3 884650-98-0 99.76%
    Mpro inhibitor N3 is a potent SARS-CoV-2 MPro inhibitor with an EC50 value of 16.77 µM. Mpro inhibitor N3 shows antiviral activities against HCoV-229E, FIPV, IBV and MHV-A59.
    Mpro inhibitor N3
  • HY-147255
    Canocapavir 2137847-19-7 98.91%
    Canocapavir (ZM-H1505R) is an orally active HBV core protein-targeting antiviral agent. Canocapavir binds to the hydrophobic pocket at the dimer-dimer interface of HBV core protein (HBc), stimulating intracellular accumulation of nonfunctional HBV capsids, disrupting viral replication. Canocapavir interferes with the interaction between HBc and HBV large surface protein, resulting in diminished
    production of empty virionsis. Canocapavir can be used for the research of hepatitis B virus (HBV) infection.
    Canocapavir
  • HY-148191
    CL-197 1030595-07-3 99.32%
    CL-197 is an orally active and long-acting purine anti-HIV nucleoside reverse transcriptase inhibitor (NRTI). CL-197 has potential effect on the research of viral, oncological and cerebrovascular diseases. CL-197 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CL-197
  • HY-15440B
    Fostemsavir Tris 864953-39-9 99.78%
    Fostemsavir Tris (BMS-663068 (Tris)) is the phosphonooxymethyl proagent of BMS-626529. Fostemsavir Tris (BMS-663068 (Tris)) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells.
    Fostemsavir Tris
  • HY-P3383A
    Peceleganan acetate 98.36%
    Peceleganan (PL-5) acetate is an artificial antimicrobial cecropin A (1-10) × melittin B (3-18) hybrid (10+16)-peptide analogue. Peceleganan acetate inhibits wound infection.
    Peceleganan acetate
Cat. No. Product Name / Synonyms Application Reactivity